MRP4-mediated regulation of intracellular cAMP and cGMP levels in trabecular meshwork cells and homeostasis of intraocular pressure

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 3, 2013, Pages 1636-1649

  Pattabiraman, Padmanabhan P ^a   Pecen, Paula E ^a   Rao, Ponugoti Vasantha ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ISOBUTYLMETHYLXANTHINE; MULTIDRUG RESISTANCE PROTEIN 4; MYOSIN LIGHT CHAIN; PROBENECID; QUERCETIN; SMALL INTERFERING RNA; VERLUKAST;

ACTIN FILAMENT; ANIMAL EXPERIMENT; AQUEOUS HUMOR; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; INTRAOCULAR PRESSURE; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRABECULAR MESHWORK;

ACTINS; ADULT; AGED; ANIMALS; AQUEOUS HUMOR; CELLS, CULTURED; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; HOMEOSTASIS; HUMANS; INTRAOCULAR PRESSURE; LEUKOTRIENE ANTAGONISTS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MYOSIN LIGHT CHAINS; PHOSPHORYLATION; PROBENECID; PROPIONATES; QUINOLINES; RABBITS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK;

EID: 84875629321     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11107     Document Type: Article

References (63)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-267.
2. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363:1711-1720.
3. Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary openangle glaucoma. N Engl J Med. 2009;360:1113-1124.
4. Gabelt BT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. Prog Retin Eye Res. 2005;24:612-637.
5. Rao VPED. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs. 2007;21:167-177.
6. Russell P, Johnson M. Elastic modulus determination of normal and glaucomatous human trabecular meshwork. Invest Ophthalmol Vis Sci. 2012;53:117.
7. Wiederholt M, Thieme H, Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog Retin Eye Res. 2000;19:271-295.
8. Tan JC, Peters DM, Kaufman PL. Recent developments in understanding the pathophysiology of elevated intraocular pressure. Curr Opin Ophthalmol. 2006;17:168-174.
9. Pattabiraman PP, Rao PV. Mechanistic basis of Rho GTPaseinduced extracellular matrix synthesis in trabecular meshwork cells. Am J Physiol Cell Physiol. 2010;298:C749-C763.
10. Epstein DL, Rowlette LL, Roberts BC. Acto-myosin drug effects and aqueous outflow function. Invest Ophthalmol Vis Sci. 1999;40:74-81.
11. Tian B, Brumback LC, Kaufman PL. ML-7, chelerythrine and phorbol ester increase outflow facility in the monkey Eye. Exp Eye Res. 2000;71:551-566.
12. Khurana RN, Deng PF, Epstein DL, Vasantha Rao P. The role of protein kinase C in modulation of aqueous humor outflow facility. Exp Eye Res. 2003;76:39-47.
13. Alexander JP, Acott TS. Involvement of the Erk-MAP kinase pathway in TNFalpha regulation of trabecular matrix metalloproteinases and TIMPs. Invest Ophthalmol Vis Sci. 2003;44: 164-169.
14. Husain S, Shearer TW, Crosson CE. Mechanisms linking adenosine A1 receptors and extracellular signal-regulated kinase 1/2 activation in human trabecular meshwork cells. J Pharmacol Exp Ther. 2007;320:258-265.
15. Wang WH, McNatt LG, Pang IH, et al. Increased expression of the WNT antagonist sFRP-1 in glaucoma elevates intraocular pressure. J Clin Invest. 2008;118:1056-1064.
16. Mao W, Millar JC, Wang WH, et al. Existence of the canonical Wnt signaling pathway in the human trabecular meshwork. Invest Ophthalmol Vis Sci. 2012;53:7043-7051.
17. Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137-144.
18. Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42:1029-1037.
19. Gilabert R, Gasull X, Pales J, Belmonte C, Bergamini MV, Gual A. Facility changes mediated by cAMP in the bovine anterior segment in vitro. Vision Res. 1997;37:9-15.
20. Bartels SP, Lee SR, Neufeld AH. Forskolin stimulates cyclic AMP synthesis, lowers intraocular pressure and increases outflow facility in rabbits. Curr Eye Res. 1982;2:673-681.
21. Murthy KS. Signaling for contraction and relaxation in smooth muscle of the gut. Annu Rev Physiol. 2006;68:345-374.
22. Derbyshire ER, Marletta MA. Structure and regulation of soluble guanylate cyclase. Annu Rev Biochem. 2012;81:533-559.
23. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991; 43:109-142.
24. Zhou L, Thompson WJ, Potter DE. Functional identification of phosphodiesterase activity in human trabecular meshwork cells. J Ocul Pharmacol Ther. 2000;16:317-322.
25. Suzuki R, Karageuzian LN, Crean EV, Anderson PJ. Effects of adrenergic agents and phosphodiesterase inhibitors on outflow facility and cell shape of bovine trabecular meshwork. Jpn J Ophthalmol. 1997;41:31-37.
26. Zhou L, Thompson WJ, Potter DE. Multiple cyclic nucleotide phosphodiesterases in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1999;40:1745-1752.
27. Busch MJ, Kobayashi K, Hoyng PF, Mittag TW. Adenylyl cyclase in human and bovine trabecular meshwork. Invest Ophthalmol Vis Sci. 1993;34:3028-3034.
28. Zhang X, Wang N, Schroeder A, Erickson KA. Expression of adenylate cyclase subtypes II and IV in the human outflow pathway. Invest Ophthalmol Vis Sci. 2000;41:998-1005.
29. Haque MS, Pang IH, Magnino PE, DeSantis L. Activation of phospholipase C and guanylyl cyclase by endothelins in human trabecular meshwork cells. Curr Eye Res. 1998;17: 1110-1117.
30. Ellis DZ. Guanylate cyclase activators, cell volume changes and IOP reduction. Cell Physiol Biochem. 2011;28:1145-1154.
31. Russel FG, Koenderink JB, Masereeuw R. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol Sci. 2008; 29:200-207.
32. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002;71:537-592.
33. Schuetz JD, Connelly MC, Sun D, et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med. 1999;5:1048-1051.
34. Reid G, Wielinga P, Zelcer N, et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003;100:9244-9249.
35. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002;13: 595-603.
36. Wielinga PR, van der Heijden I, Reid G, Beijnen JH, Wijnholds J, Borst P. Characterization of the MRP4-and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem. 2003;278:17664-17671.
37. Sassi Y, Lipskaia L, Vandecasteele G, et al. Multidrug resistanceassociated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation. J Clin Invest. 2008;118:2747-2757.
38. Hara Y, Sassi Y, Guibert C, et al. Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J Clin Invest. 2011;121:2888-2897.
39. Pattabiraman PP, Lih FB, Tomer KB, Rao PV. The role of calcium-independent phospholipase A2gamma in modulation of aqueous humor drainage and Ca2{thorn} sensitization of trabecular meshwork contraction. Am J Physiol Cell Physiol. 2012;302:C979-C991.
40. Iyer P, Lalane R III, Morris C, Challa P, Vann R, Rao PV. Autotaxin-lysophosphatidic acid axis is a novel molecular target for lowering intraocular pressure. PLoS One. 2012;7: e42627.
41. Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci. 2001;22:32-39.
42. Lang P, Gesbert F, Delespine-Carmagnat M, Stancou R, Pouchelet M, Bertoglio J. Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. EMBO J. 1996;15:510-519.
43. Ellerbroek SM, Wennerberg K, Burridge K. Serine phosphorylation negatively regulates RhoA in vivo. J Biol Chem. 2003; 278:19023-19031.
44. Feng J, Ito M, Ichikawa K, et al. Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J Biol Chem. 1999;274:37385-37390.
45. Francis SH, Corbin JD. Structure and function of cyclic nucleotide-dependent protein kinases. Annu Rev Physiol. 1994;56:237-272.
46. Kwiatkowski AV, Gertler FB, Loureiro JJ. Function and regulation of Ena/VASP proteins. Trends Cell Biol. 2003;13: 386-392.
47. Joshi CN, Martin DN, Fox JC, Mendelev NN, Brown TA, Tulis DA. The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMPdependent protein kinase and cGMP-dependent protein kinase pathways. J Pharmacol Exp Ther. 2011;339:394-402.
48. Busch MJ, van Oosterhout EJ, Hoyng PF. Effects of cyclic nucleotide analogs on intraocular pressure and traumainduced inflammation in the rabbit eye. Curr Eye Res. 1992; 11:5-13.
49. Dismuke WM, Mbadugha CC, Ellis DZ. NO-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channel. Am J Physiol Cell Physiol. 2008;294:C1378-C1386.
50. Kaufman PL. Adenosine 30,50-cyclic-monophosphate and outflow facility in monkey eyes with intact and retrodisplaced ciliary muscle. Exp Eye Res. 1987;44:415-423.
51. Kee C, Kaufman PL, Gabelt BT. Effect of 8-Br cGMP on aqueous humor dynamics in monkeys. Invest Ophthalmol Vis Sci. 1994;35:2769-2773.
52. Busch MJ, Hoyng PF. Evaluation of IBMX-enhanced ocular hypotension after adrenergic agonists in the rabbit eye. Graefes Arch Clin Exp Ophthalmol. 1995;233:296-301.
53. Crosson CE, Gray T. Modulation of intraocular pressure by adenosine agonists. J Ocul Pharmacol. 1994;10:379-383.
54. Schneemann A, Dijkstra BG, van den Berg TJ, Kamphuis W, Hoyng PF. Nitric oxide/guanylate cyclase pathways and flow in anterior segment perfusion. Graefes Arch Clin Exp Ophthalmol. 2002;240:936-941.
55. Stein PJ, Clack JW. Topical application of a cyclic GMP analog lowers IOP in normal and ocular hypertensive rabbits. Invest Ophthalmol Vis Sci. 1994;35:2765-2768.
56. Sassi Y, Abi-Gerges A, Fauconnier J, et al. Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes. FASEB J. 2012;26:1009-1017.
57. Reid G, Wielinga P, Zelcer N, et al. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003; 63:1094-1103.
58. Hofmann F, Feil R, Kleppisch T, Schlossmann J. Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev. 2006;86:1-23.
59. Ramachandran C, Patil RV, Sharif NA, Srinivas SP. Effect of elevated intracellular cAMP levels on actomyosin contraction in bovine trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2011;52:1474-1485.
60. Francis SH, Busch JL, Corbin JD, Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010;62:525-563.
61. Dai S, Hall DD, Hell JW. Supramolecular assemblies and localized regulation of voltage-gated ion channels. Physiol Rev. 2009;89:411-452.
62. Williams RD, Novack GD, van Haarlem T, Kopczynski C. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011;152:834-841. e1.
63. Abla N, Chinn LW, Nakamura T, et al. The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther. 2008;325: 859-868.